
Please try another search
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company’s stem cell derived Exosome Technology platform offers a delivery mechanism for a variety of payloads, such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. The Company has two clinical-stage stem cell therapy candidate assets, a Phase 2a human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa and a Phase 2b immortalized neural progenitor cell therapy candidate (CTX) in stroke. The Company through its induced pluripotent stem cell (iPSC) platform has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
Name | Age | Since | Title |
---|---|---|---|
Iain Gladstone Ross | 69 | 2021 | Executive Chairman |
Michael John Owen | 72 | 2015 | Independent Non-Executive Director |
Martin Charles Walton | 58 | 2022 | Independent Non-Executive Director |
Barbara Regina Staehelin | 60 | 2021 | Senior Independent Non-Executive Director |
John Michael Hawkins | 57 | 2021 | CFO & Director |
Giuseppe Battaglia | - | 2023 | Member of Scientific Advisory Board |
Kenneth W. Witwer | - | 2023 | Member of Scientific Advisory Board |
Stefano Pluchino | - | 2021 | Chair of the Scientific Advisory Board |
Bernd Giebel | - | 2023 | Member of Scientific Advisory Board |
Edit I. Buzas | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review